Interact Cardiovasc Thorac Surg. 2006 Jun;5(3):307-10, Laisaar T, Palmiste V, Vooder T, Umbleja T., Department of Cardiovascular and Thoracic Surgery, Tartu University Clinics, Puusepa 8, 51014 Tartu, Estonia
This study was analyzed complications and survival after talc pleurodesis for malignant pleural effusion. All patients with morphologically proven malignant pleural effusion who underwent talc pleurodesis from November 1995 to November 2002 were included in retrospective analysis.
Ninety-eight patients (28 male and 70 female) with mean age 59.6 (range 18-82) years were included. Thirteen patients had a bilateral pleural effusion. The most common primary cancer sites were lung (30 cases), breast (25) and ovarium (11).
Twenty-eight patients had postoperative complications (fever in 17 cases). In seven cases pleurodesis was ineffective. Median survival was 8.4 months. Six-, 12- and 24-month survival was 58% (95% CI [0.47-0.67]), 39% [0.29-0.49] and 20% [0.12-0.29], respectively. Survival data after talc pleurodesis advocate use of this invasive treatment method despite the advanced stage of cancer.
Information about mesothelioma medical and legal options provided by the Law Office of Roger G. Worthington, P.C., www.mesothel.com.